These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
752 related articles for article (PubMed ID: 9166480)
41. Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV(> or = N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. ; Int J Radiat Oncol Biol Phys; 1996 Jun; 35(3):463-9. PubMed ID: 8655368 [TBL] [Abstract][Full Text] [Related]
42. Intensive short cause chemotherapy followed by radiotherapy of locally advanced nasopharyngeal carcinoma. Zidan J; Kuten A; Robinson E Cancer; 1996 May; 77(10):1973-7. PubMed ID: 8640658 [TBL] [Abstract][Full Text] [Related]
43. Chemotherapy of recurrent/advanced cervical cancer: results of the Yale University PBM-PFU protocol. Chambers SK; Lamb L; Kohorn EI; Schwartz PE; Chambers JT Gynecol Oncol; 1994 May; 53(2):161-9. PubMed ID: 7514557 [TBL] [Abstract][Full Text] [Related]
44. Phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in advanced/recurrent carcinoma of the uterine cervix and vagina. Long HJ; Cross WG; Wieand HS; Webb MJ; Mailliard JA; Kugler JW; Tschetter LK; Kardinal CG; Ebbert LP; Rayson S Gynecol Oncol; 1995 May; 57(2):235-9. PubMed ID: 7729741 [TBL] [Abstract][Full Text] [Related]
45. [Combination of 5-FU, high dose methotrexate, epirubicin and cisplatin (FEMTX-P protocol) in non surgical or locally recurrent metastatic gastric cancers]. Conroy T; Wils J; Paillot B; Wagener DJ; Burghouts JT; Fickers MM; de Graeff A; Lalisang FM Bull Cancer; 1993 Mar; 80(3):255-60. PubMed ID: 8173178 [TBL] [Abstract][Full Text] [Related]
46. Ifosfamide plus epirubicin at escalating doses in the treatment of locally advanced and/or metastatic sarcomas. Toma S; Palumbo R; Canavese G; Albanese E; Cantoni E; Barisone A; Reggiardo G; Rosso R; Santi L Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S222-7. PubMed ID: 8453703 [TBL] [Abstract][Full Text] [Related]
47. High complete response in advanced nasopharyngeal carcinoma with bleomycin, epirubicin, and cisplatin before radiotherapy. Bachouchi M; Cvitkovic E; Azli N; Gasmi J; Cortes-Funes H; Boussen H; Rahal M; Kalifa C; Schwaab G; Eschwege F J Natl Cancer Inst; 1990 Apr; 82(7):616-20. PubMed ID: 1690306 [TBL] [Abstract][Full Text] [Related]
48. [Induction polychemotherapy before radiotherapy in carcinoma of the cavum. The experience of the Ibn Rochd-Casablanca Oncology Centre]. Samlali R; Acharki A; Sahraoui S; Benider A; Kahlain A Bull Cancer Radiother; 1996; 83(2):111-4. PubMed ID: 8688217 [TBL] [Abstract][Full Text] [Related]
49. High-dose epirubicin and cisplatin in locally advanced undifferentiated nasopharyngeal carcinoma. Onat H; Basaran M; Esassolak M; Bavbek SE; Anacak Y; Kaytan E; Altun M; Haydaroglu A Clin Oncol (R Coll Radiol); 2002 Dec; 14(6):449-54. PubMed ID: 12512965 [TBL] [Abstract][Full Text] [Related]
50. Concomitant chemotherapy and radiotherapy for locally advanced nasopharyngeal carcinoma. Cheng SH; Liu TW; Jian JJ; Tsai SY; Hao SP; Huang CH; Liu MC; Yu B; Huang AT Cancer J Sci Am; 1997; 3(2):100-6. PubMed ID: 9099460 [TBL] [Abstract][Full Text] [Related]
51. Therapeutic efficacy of multimodal combination therapy using transcatheter arterial infusion of epirubicin and cisplatin, systemic infusion of 5-fluorouracil, and additional percutaneous ethanol injection for unresectable hepatocellular carcinoma. Jang JW; Park YM; Bae SH; Choi JY; Yoon SK; Chang UI; Nam SW; Kim BS Cancer Chemother Pharmacol; 2004 Nov; 54(5):415-20. PubMed ID: 15235823 [TBL] [Abstract][Full Text] [Related]
53. Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. Ma J; Mai HQ; Hong MH; Min HQ; Mao ZD; Cui NJ; Lu TX; Mo HY J Clin Oncol; 2001 Mar; 19(5):1350-7. PubMed ID: 11230478 [TBL] [Abstract][Full Text] [Related]
54. [Contribution of chemotherapy in the treatment of cancer of the cavum (UCNT): apropos of 47 cases]. Poupart M; Damiano J; Bolot G; Biron P; Caldentey L; Ardiet JM; Pignat JC Bull Cancer; 1994 May; 81(5):366-70. PubMed ID: 7538361 [TBL] [Abstract][Full Text] [Related]
55. Treatment of advanced or recurrent squamous cell carcinoma of the uterine cervix with mitomycin-C, bleomycin, and cisplatin chemotherapy. Smith HO; Stringer CA; Kavanagh JJ; Gershenson DM; Edwards CL; Wharton JT Gynecol Oncol; 1993 Jan; 48(1):11-5. PubMed ID: 7678571 [TBL] [Abstract][Full Text] [Related]
56. Induction chemotherapy with nedaplatin with 5-FU followed by intensity-modulated radiotherapy concurrent with chemotherapy for locoregionally advanced nasopharyngeal carcinoma. Zheng J; Wang G; Yang GY; Wang D; Luo X; Chen C; Zhang Z; Li Q; Xu W; Li Z; Wang D Jpn J Clin Oncol; 2010 May; 40(5):425-31. PubMed ID: 20085903 [TBL] [Abstract][Full Text] [Related]
57. Epirubicin and cisplatin in recurrent, metastatic or advanced carcinoma of the cervix. Lorvidhaya V Gan To Kagaku Ryoho; 1995 Aug; 22 Suppl 3():252-5. PubMed ID: 7661592 [TBL] [Abstract][Full Text] [Related]
58. Phase II study of docetaxel, cisplatin, and 5-FU induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal cancer. Bae WK; Hwang JE; Shim HJ; Cho SH; Lee JK; Lim SC; Chung WK; Chung IJ Cancer Chemother Pharmacol; 2010 Feb; 65(3):589-95. PubMed ID: 19830427 [TBL] [Abstract][Full Text] [Related]
59. Long-term follow-up of a pilot phase II study with neoadjuvant epidoxorubicin, etoposide and cisplatin in gastric cancer. Barone C; Cassano A; Pozzo C; D'Ugo D; Schinzari G; Persiani R; Basso M; Brunetti IM; Longo R; Picciocchi A Oncology; 2004; 67(1):48-53. PubMed ID: 15459495 [TBL] [Abstract][Full Text] [Related]
60. A phase II study of etoposide, cisplatin, and doxorubicin chemotherapy in mixed müllerian tumors (MMT) of the uterus. Resnik E; Chambers SK; Carcangiu ML; Kohorn EI; Schwartz PE; Chambers JT Gynecol Oncol; 1995 Mar; 56(3):370-5. PubMed ID: 7705670 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]